Step 1 topics → Respiratory → Small Cell Lung Cancer

Small Cell Lung Cancer

USMLE Step 1 trap: Misplaces SCLC as a peripheral tumor rather than a central one. SCLC arises centrally near the mainstem bronchi, similar to squamous cell carcinoma.

Small cell lung cancer (SCLC) is a high-yield neuroendocrine tumor that USMLE Step 1 loves to test because it sits at the intersection of pathology, pharmacology, and clinical medicine. It arises centrally, grows aggressively, and almost always presents with metastatic disease — which completely dictates how it's treated. The exam will push you on two main angles: the histological and molecular identity of the tumor itself, and the paraneoplastic syndromes it produces. Expect vignettes that bury the lung cancer diagnosis in a clinical scenario dominated by hyponatremia, Cushing features, or proximal muscle weakness.

What makes SCLC consistently tricky on Step 1 is that students conflate it with other lung cancers or with other diseases entirely. The paraneoplastic syndromes are the biggest trap: SIADH and ectopic ACTH production are both classic SCLC associations, but students confuse ectopic ACTH with pituitary-driven Cushing disease and miss the key dexamethasone suppression distinction. Lambert-Eaton syndrome gets mixed up with myasthenia gravis constantly — both cause proximal muscle weakness, but the physiologic mechanism runs in opposite directions. These aren't subtle nuances; they're direct test points.

Management questions are another USMLE Step 1 favorite. The key fact is that surgery is essentially never done for SCLC — the disease is almost always disseminated at diagnosis, so the backbone of treatment is chemotherapy (etoposide + platinum) ± radiation. Students who default to 'surgery + chemo' for lung cancer will get this wrong. Locking in the central location, neuroendocrine identity, paraneoplastic profiles, and chemo-based management is how you own this topic.

From real student decks
68%have cards covering this topic
49%have mature cards

Common misconceptions

Common mistake
Wrong: SCLC arises peripherally like adenocarcinoma.
Right: SCLC arises centrally near the mainstem bronchi, similar to squamous cell carcinoma.
Students often lump SCLC with adenocarcinoma as a peripheral tumor, but this is wrong. SCLC arises centrally, near the mainstem bronchi, from neuroendocrine Kulchitsky cells in the bronchial mucosa — the same general territory as squamous cell carcinoma. Peripheral location on imaging should redirect you toward adenocarcinoma or carcinoid, not SCLC.
Common mistake
Wrong: Cushing syndrome from SCLC is caused by pituitary ACTH overproduction.
Right: SCLC causes ectopic ACTH production by the tumor itself, leading to Cushing syndrome with very high ACTH levels that are not suppressed by high-dose dexamethasone.
Ectopic ACTH in SCLC is not the same as pituitary Cushing disease, and the exam tests this distinction directly. In pituitary disease, high-dose dexamethasone suppresses ACTH because the pituitary retains negative feedback sensitivity. In SCLC, the tumor itself secretes ACTH autonomously — there is no feedback suppression, so ACTH and cortisol remain elevated even with high-dose dexamethasone. The ACTH level is also often dramatically high, and patients may have more hyperpigmentation and hypokalemia than classic Cushing features.
Common mistake
Wrong: Lambert-Eaton syndrome presents identically to myasthenia gravis with worsening weakness on repeated use.
Right: Lambert-Eaton syndrome shows improvement with repeated muscle use (facilitation) because repeated stimulation increases calcium-dependent ACh release, unlike myasthenia gravis which worsens.
In myasthenia gravis, antibodies block postsynaptic ACh receptors, so repeated use depletes effective neurotransmission and causes progressive weakness. Lambert-Eaton is mechanistically opposite: antibodies attack presynaptic voltage-gated calcium channels, reducing ACh release at baseline — but repeated stimulation builds up intracellular calcium and transiently increases ACh release, causing brief improvement with repeated muscle use (facilitation). This 'warming up' pattern is the key clinical distinguisher.
Common mistake
Wrong: Surgery is a standard treatment option for SCLC.
Right: SCLC is almost never treated surgically because it is nearly always metastatic at diagnosis; treatment is chemotherapy (etoposide + platinum) with or without radiation.
The reason surgery is off the table for SCLC is not arbitrary — it's because SCLC has almost invariably metastasized by the time of diagnosis, making local resection futile. The biology demands systemic therapy. Chemotherapy with etoposide plus a platinum agent is the foundation; radiation is added for limited-stage disease or for prophylactic cranial irradiation. Defaulting to surgery because 'it's lung cancer' is the classic trap Step 1 sets for this topic.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Identify SCLC as a centrally located tumor arising near the mainstem bronchi from neuroendocrine (Kulchitsky) cells, and recognize its strong association with heavy smoking.
  2. Recognize SCLC on histology as sheets of small, round, hyperchromatic cells with scant cytoplasm and neuroendocrine marker expression (chromogranin, synaptophysin, CD56), plus TP53 and RB1 loss.
  3. Match each SCLC paraneoplastic syndrome to its mechanism: SIADH (ectopic ADH → hyponatremia), ectopic ACTH (high ACTH not suppressed by high-dose dexamethasone → Cushing), and Lambert-Eaton (autoantibodies against presynaptic VGCC → proximal weakness that improves with repeated use).
  4. Select the correct treatment for limited-stage vs. extensive-stage SCLC: chemoradiation for limited stage, chemotherapy alone (etoposide + cisplatin/carboplatin) for extensive stage — and recognize that surgery has no standard role.

Can you avoid these mistakes?

A 58-year-old smoker presents with profound hyponatremia and is found to have a central hilar mass on CT. Biopsy shows small, round cells with scant cytoplasm staining positive for synaptophysin. What is the diagnosis, and what electrolyte abnormality mechanism explains this presentation?
A patient with known SCLC develops truncal obesity, hypertension, and hypokalemic alkalosis. ACTH level is markedly elevated and cortisol is not suppressed by high-dose dexamethasone overnight. Why does the dexamethasone suppression test fail here, and how does this differ from a pituitary adenoma causing Cushing disease?
A 62-year-old man presents with proximal leg weakness that seems to improve slightly after walking up a flight of stairs. EMG shows incremental response with repetitive stimulation. What syndrome is this, what cancer must you rule out, and what is the underlying antibody target?
A patient is diagnosed with extensive-stage SCLC. A surgical resident suggests lobectomy followed by adjuvant chemotherapy. Why is this approach incorrect, and what is the standard treatment regimen for this stage?

Related topics

Lung Cancer Overview and Screening Lung Development Stages Surfactant Production and Neonatal RDS Bronchopulmonary Dysplasia Congenital Diaphragmatic Hernia

See how your Anki deck covers this topic.

Upload your deck for a free audit →